Our round-up of recent biotech financings is headed by a $250 million public offering for late clinical-stage biotech Vera Therapeutics, with an initial public offering (IPO) filed by CAR-T ...

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of ...

Dr. Vera will join company executives and key opinion leaders to discus HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology ...

About Protagonist Therapeutics Protagonist Therapeutics is ... is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will ...

Protagonist Therapeutics is a discovery through late ... is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be ...

Sustainalytics’ controversies research identifies companies involved in incidents and events that may negatively affect stakeholders, the environment or the company’s operations. Controversies are ...

and Vera Therapeutics’ atacicept, which are already in phase 3 and so one to two years ahead in development. That said, they believe Alpine’s drug has best-in-class potential as a result of ...